- CH₣31.10bn
- CH₣34.30bn
- $11.16bn
Brief: Sandoz Confirms European Commission Approval Of Ondibta, Expects Launch By Early 2027
Insight: Pills, TikTok and weight-loss apps: the consumer-driven future of GLP-1s
Europe Research Roundup: Auto1 Group, Roche Holding, Sanofi
Brief: Sandoz Completes Strategic Acquisition Of Just-Evotec Biologics EU Sas, Asserting Biosimilars Leadership
Brief: Sandoz Launches Denosumab Biosimilars In Europe
Press Digest: Canada - Nov 21
Sandoz CEO expects Ozempic biosimilars to enter Canadian market in Q1, Q2 (updated)
Sandoz CEO expects Ozempic biosimilars to enter Canadian market in Q1, Q2
Brief: Sandoz Signs Global License Agreement With Eirgenix To Commercialize Pertuzumab
Europe Research Roundup: Finecobank, Rightmove, Sandoz Group
Swiss stocks - Factors to watch on November 10
Brief: BRIEF TEMPLATE
Europe Research Roundup: Capgemini,Ryanair, TKH Group
Swiss stocks - Factors to watch on November 3
Drugmakers must face skincare drug price-fixing lawsuit, US judge rules
Swiss stocks - Factors to watch on October 30
Brief: Sandoz Says Group Q3 Net Sales At $2.8 Bln
Europe Research Roundup: Aurubis, Nestle, Playtech
Swiss stocks - Factors to watch on October 17